Charles Cholsoo Lho is a highly influential figure in the Asian private equity and venture capital landscape, currently serving as the Chairman of H&Q Asia Pacific (HQAP). With a distinguished career spanning over three decades, he has been instrumental in pioneering and shaping the private equity investment scene in Korea and across the broader Asian continent. Mr. Lho joined H&Q Asia Pacific in 1989 and has since driven the firm's strategy, leading it to become a prominent player known for landmark deals and fostering significant growth in various industries. His expertise encompasses cross-border investments, mergers and acquisitions, and identifying and nurturing high-potential companies. Before his significant impact in finance, he also had involvement with the Lhoist Group, a global leader in lime and minerals, reflecting a diverse business background. He is widely recognized for his strategic foresight, deep market understanding, and significant contributions to the economic development and financial sector maturation in the region.
Charles Cholsoo Lho's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:
Played a foundational role in establishing and developing the private equity market in South Korea through his leadership at H&Q Asia Pacific, introducing sophisticated investment strategies and governance.
As Chairman, successfully steered H&Q Asia Pacific to become a leading private equity firm in Asia, overseeing numerous successful investments, exits, and fundraisings, significantly expanding its portfolio and regional influence.
Instrumental in structuring and executing numerous significant cross-border investments and M&A transactions, effectively bridging Western capital with Asian growth opportunities and vice-versa.
Spearheaded and managed highly successful investments in notable companies across various sectors, such as the investment in Starbucks Korea (through Shinsegae Group) and Ssangyong Securities, contributing to their substantial growth and market leadership.
Made significant contributions to the development and sophistication of financial markets in Asia, particularly in private equity, fostering best practices and attracting international investor interest.
Oxford University - Year 1990
Yale University - Yale School of Management - Year 1983
Stanford University - Year 1975
Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Their primary areas of focus include lysosomal storage disorders, with a commitment to advancing innovative treatments from research through to commercialization to improve the lives of patients and their families worldwide.
Get verified emails, phone numbers, and LinkedIn profile details
Discover contacts with similar roles, seniority, or companies
Uncover insights like skills, work history, social links, and more
Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.
Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.
Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.
Thousands of companies, including, are just a search away.